Asunto(s)
Agammaglobulinemia/inmunología , Agammaglobulinemia/virología , Enfermedades Genéticas Ligadas al Cromosoma X/inmunología , Enfermedades Genéticas Ligadas al Cromosoma X/virología , Kobuvirus/inmunología , Infecciones por Picornaviridae/inmunología , Infecciones por Picornaviridae/virología , Virosis/inmunología , Adolescente , Enfermedad Crónica , Enfermedad Injerto contra Huésped/inmunología , Enfermedad Injerto contra Huésped/virología , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Masculino , Virosis/virologíaAsunto(s)
Agammaglobulinemia/diagnóstico , Envejecimiento/patología , COVID-19/diagnóstico , Neumonía/diagnóstico , Neumonía/etiología , Agammaglobulinemia/virología , Anciano , COVID-19/virología , Humanos , Masculino , Persona de Mediana Edad , Pandemias/prevención & control , Neumonía/virología , SARS-CoV-2/patogenicidadRESUMEN
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease affecting the central nervous system as a result of reactivation of the John Cunningham (JC) polyomavirus and occurs almost exclusively in immunosuppressed individuals. The disease course of PML is variable but usually progressive and often fatal. Treatment is predominantly focused on immune restoration, although this is difficult to do outside of human immunodeficiency virus-associated PML. A recent case series demonstrated a potential role for programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab, to contain and/or clear JC virus. Herein, we discuss the first reported Australian case of a 61-year-old female with PML secondary to chemoimmunotherapy demonstrating complete clearance of JC virus as well as clinical and radiological stabilisation following pembrolizumab treatment.
Asunto(s)
Agammaglobulinemia/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Hipertensión/tratamiento farmacológico , Leucoencefalopatía Multifocal Progresiva/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Agammaglobulinemia/diagnóstico por imagen , Agammaglobulinemia/inmunología , Agammaglobulinemia/virología , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Encéfalo/virología , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/virología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/virología , Femenino , Humanos , Hipertensión/diagnóstico por imagen , Hipertensión/inmunología , Hipertensión/virología , Virus JC/efectos de los fármacos , Virus JC/crecimiento & desarrollo , Virus JC/inmunología , Leucoencefalopatía Multifocal Progresiva/diagnóstico por imagen , Leucoencefalopatía Multifocal Progresiva/inmunología , Leucoencefalopatía Multifocal Progresiva/virología , Activación de Linfocitos/efectos de los fármacos , Linfoma/diagnóstico por imagen , Linfoma/inmunología , Linfoma/virología , Imagen por Resonancia Magnética , Persona de Mediana Edad , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Receptor de Muerte Celular Programada 1/genética , Receptor de Muerte Celular Programada 1/inmunología , Resultado del TratamientoRESUMEN
INTRODUCTION: Chronic enterovirus infections can occur in primary immunodeficiency with hypogammaglobulinemia. They usually associate meningitis and myofasciitis. Such infections have also been described in adults with rituximab-induced hypogammaglobulinemia. CASE REPORT: We report the case of a 33-year-old woman who was given rituximab for immune thrombocytopenia and developed rituximab-induced hypogammaglobulinemia (IgG 4.4g/L). One year after the last rituximab infusion, she developed lower limbs myofasciitis, followed two months later by a chronic lymphocytic meningitis. PCR in the serum and the cerebrospinal fluid at the time of the meningitis and the myofasciitis were positive to the same enterovirus (echovirus 11) while it was negative in the fascia biopsy. Under treatment with intravenous immunoglobulins, all symptoms and laboratory abnormalities improved and enterovirus PCR became negative. CONCLUSION: We report a case of chronic enterovirus infection associating meningitis and myofasciitis in an adult with rituximab-induced hypogammaglobulinemia. Outcome was favorable under treatment with intravenous immunoglobulins.
Asunto(s)
Agammaglobulinemia/inducido químicamente , Infecciones por Enterovirus/inducido químicamente , Rituximab/efectos adversos , Adulto , Agammaglobulinemia/virología , Enfermedad Crónica , Infecciones por Enterovirus/inmunología , Infecciones por Enterovirus/terapia , Fascitis/inducido químicamente , Fascitis/terapia , Femenino , Francia , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Meningitis/inducido químicamente , Meningitis/complicaciones , Meningitis/terapia , Miositis/inducido químicamente , Miositis/complicaciones , Miositis/terapia , Púrpura Trombocitopénica Idiopática/tratamiento farmacológicoRESUMEN
Good's syndrome is a primary immunodeficiency phenocopy characterized for thymoma and immunodeficiency. The most frequent clinical presentation is recurrent or opportunistic infections, hematological alterations, and chronic diarrhea. We treated a 66-year-old man who consulted for 5 days of headache and diplopia with right sixth cranial nerve palsy at examination. Patient reported chronic diarrhea and prolonged febrile syndrome accompanied by weight loss of 23 kg in the last year. Exhaustive evaluation revealed Herpes simplex virus (HSV) type 2 meningitis, eosinophilic colitis, and type A thymoma. Severe antibody deficiency (hypogammaglobulinemia) associated with thymoma confirmed the diagnosis of Good's syndrome.
Asunto(s)
Agammaglobulinemia/patología , Colitis/patología , Enfermedades de los Nervios Craneales/patología , Herpes Simple/patología , Herpesvirus Humano 2/patogenicidad , Meningitis Viral/patología , Neoplasias Glandulares y Epiteliales/patología , Neoplasias del Timo/patología , Agammaglobulinemia/diagnóstico , Agammaglobulinemia/inmunología , Agammaglobulinemia/virología , Anciano , Colitis/diagnóstico , Colitis/inmunología , Colitis/virología , Enfermedades de los Nervios Craneales/diagnóstico , Enfermedades de los Nervios Craneales/inmunología , Enfermedades de los Nervios Craneales/virología , Diplopía/diagnóstico , Diplopía/inmunología , Diplopía/patología , Diplopía/virología , Eosinofilia/diagnóstico , Eosinofilia/inmunología , Eosinofilia/patología , Eosinofilia/virología , Cefalea/diagnóstico , Cefalea/inmunología , Cefalea/patología , Cefalea/virología , Herpes Simple/diagnóstico , Herpes Simple/inmunología , Herpes Simple/virología , Herpesvirus Humano 2/crecimiento & desarrollo , Herpesvirus Humano 2/inmunología , Humanos , Recuento de Linfocitos , Masculino , Meningitis Viral/diagnóstico , Meningitis Viral/inmunología , Meningitis Viral/virología , Neoplasias Glandulares y Epiteliales/diagnóstico , Neoplasias Glandulares y Epiteliales/inmunología , Neoplasias Glandulares y Epiteliales/virología , Neoplasias del Timo/diagnóstico , Neoplasias del Timo/inmunología , Neoplasias del Timo/virologíaAsunto(s)
Agammaglobulinemia/tratamiento farmacológico , Antivirales/uso terapéutico , Enfermedades Genéticas Ligadas al Cromosoma X/tratamiento farmacológico , Hepatitis C Crónica/tratamiento farmacológico , 2-Naftilamina , Administración Oral , Adulto , Agammaglobulinemia/sangre , Agammaglobulinemia/virología , Anilidas/uso terapéutico , Carbamatos/uso terapéutico , Ciclopropanos , Enfermedades Genéticas Ligadas al Cromosoma X/sangre , Enfermedades Genéticas Ligadas al Cromosoma X/virología , Hepacivirus , Hepatitis C Crónica/sangre , Hepatitis C Crónica/diagnóstico , Hepatitis C Crónica/virología , Humanos , Imidazoles/uso terapéutico , Inmunoglobulina G/sangre , Inmunoglobulinas Intravenosas/uso terapéutico , Lactamas Macrocíclicas , Compuestos Macrocíclicos/uso terapéutico , Persona de Mediana Edad , Prolina/análogos & derivados , Pirrolidinas , Ritonavir/uso terapéutico , Sofosbuvir/uso terapéutico , Sulfonamidas/uso terapéutico , Uracilo/análogos & derivados , Uracilo/uso terapéutico , Valina/análogos & derivadosRESUMEN
MicroRNAs (miRNAs) are short, single stranded, non-coding RNA molecules. They are produced by many different species and are key regulators of several physiological processes. miRNAs are also encoded by the genomes of multiple virus families, such as herpesvirus family. In particular, miRNAs from Epstein Barr virus were found at high concentrations in different associated pathologies, such as Burkitt's lymphoma, Hodgkin disease, and nasopharyngeal carcinoma. Thanks to their stability, these molecules could possibly serve as biomarkers for EBV-associated diseases. In this study, a stem-loop real-time PCR for miR-BART2-5p, miR-BART15, and miR-BART22 EBV miRNAs detection and quantification has been developed. Evaluation of these miRNAs in 31 serum samples (12 from patients affected by primary immunodeficiency, 9 from X-linked agammaglobulinemia and 10 from healthy subjects) has been carried out. The amplification performance showed a wide dynamic range (10(8)-10(2) copies/reaction) and sensibility equal to 10(2) copies/reaction for all the target tested. Serum samples analysis, on the other hand, showed a statistical significant higher level of miR-BART22 in primary immunodeficiency patients (P = 0.0001) compared to other groups and targets. The results confirmed the potential use of this assay as a tool for monitoring EBV-associated disease and for miRNAs expression profile analysis.
Asunto(s)
Herpesvirus Humano 4/genética , MicroARNs/sangre , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Agammaglobulinemia/sangre , Agammaglobulinemia/virología , Enfermedades Genéticas Ligadas al Cromosoma X/sangre , Enfermedades Genéticas Ligadas al Cromosoma X/virología , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Síndromes de Inmunodeficiencia/sangre , Síndromes de Inmunodeficiencia/virología , Secuencias Invertidas Repetidas , MicroARNs/química , ARN Viral/sangre , ARN Viral/química , Reacción en Cadena en Tiempo Real de la Polimerasa/economía , Sensibilidad y EspecificidadRESUMEN
The results of virologic testing of clinical materials and epidemiological analysis of vaccine-associated paralytic poliomyelitis (VAPP) cases obtained in 2006-2013 during AFP surveillance are presented. Among the 2976 cases of AFP 30 cases were VAPP. 15 cases were observed in OPV recipients, whereas 15 cases were observed in non-vaccinated contacts. The age of the patients varied from 4 months to 5.5 years (13.6 ± 12.4 months old). Children younger than 1 year constituted 63.3% of the group; boys were dominant (73.3%); 53.3% of children were vaccinated with OPV; the time period between receipt of OPV and onset of palsy was from 2 to 32 days (18.7 ± 8.2). Lower paraparesis was documented in 48.3% of patients; lower monoparesis in 37.9%; upper monoparesis, in 6.9%; tetraparesis with bulbar syndrome, in 6%. The majority of the patients (85.7%) had an unfavorable premorbid status. The violations of the humoral immunity were found in 73.9% cases: CVID (52.9%), hypogammaglobulinemia (41.2%); selective lgA deflciency (5.9%). In 70.6% cases damage to humoral immunity was combined with poor premorbid status. The most frequently observed (76%, p < 0.05) represented the single type of poliovirus--type 2 (44%) and type 3 (32%). All strains were of the vaccine origin, the divergence from the homotypic Sabin strains fell within the region of the gene encoding VPI protein, which did not exceed 0.5% of nucleotide substitutions except vaccine derived poliovirus type 2--multiple recombinant (type 2/type 3/ type 2/type 1) with the degree of the divergence of 1.44% isolated from 6-month old unvaccinated child (RUS08063034001). The frequency of the VAPP cases was a total of 1 case per 3.4 million doses of distributed OPV in 2006-2013; 2.2 cases per 1 million of newborns were observed. This frequency decreased after the introduction of the sequential scheme of vaccination (IPV, OPV) in 2008-2013 as compared with the period of exclusive use of OPV in 2006-2007: 1 case per 4.9 million doses, 1.4 cases per million newborns and 1 case per 1.9 million doses, 4.9 cases per 1 million newborns, respectively. The study has been financed from Russian Federation budget within the framework of the Program for eradication of poliomyelitis in the Russian Federation, WHO Polio eradication initiative, WHO's European Regional Bureau, Russian Foundation for Basic Research (project No. 15-15-00147).
Asunto(s)
Poliomielitis/inducido químicamente , Poliomielitis/epidemiología , Vacuna Antipolio de Virus Inactivados/efectos adversos , Vacuna Antipolio Oral/efectos adversos , Poliovirus/inmunología , Vacunación , Agammaglobulinemia/epidemiología , Agammaglobulinemia/etiología , Agammaglobulinemia/inmunología , Agammaglobulinemia/virología , Niño , Preescolar , Femenino , Genotipo , Humanos , Deficiencia de IgA/epidemiología , Deficiencia de IgA/etiología , Deficiencia de IgA/inmunología , Deficiencia de IgA/virología , Inmunidad Humoral/efectos de los fármacos , Esquemas de Inmunización , Lactante , Recién Nacido , Masculino , Poliomielitis/inmunología , Poliomielitis/virología , Poliovirus/clasificación , Poliovirus/efectos de los fármacos , Poliovirus/genética , Vacuna Antipolio de Virus Inactivados/administración & dosificación , Vacuna Antipolio de Virus Inactivados/inmunología , Vacuna Antipolio Oral/administración & dosificación , Vacuna Antipolio Oral/inmunología , Federación de Rusia/epidemiologíaRESUMEN
X-linked agammaglobulinemia (XLA) has been associated with a broad range of infections, but enteroviral disease represents one of the most damaging infections. The risk of enteroviral infection in XLA is lower now than in the setting of intramuscular immunoglobulin or in patients without immunoglobulin replacement, but the rate of infection has not declined significantly in the era of intravenous immunoglobulin replacement. Enteroviruses can cause inflammation of nearly every organ, but in XLA, infections often manifest as dermatomyositis or chronic meningoencephalitis. Difficulty and delay in recognizing symptoms and lack of specific therapy contribute to the poor outcomes. Furthermore, cerebrospinal fluid detection of enteroviruses is not very sensitive. Reluctance to perform brain biopsies can lead to significant delays. The other feature compromising outcomes is the lack of specific therapy. High-dose peripheral and intraventricular immunoglobulin have been used, but failure is still common. New antienteroviral drugs are in development and show promise for immunodeficient patients with life-threatening infections with enterovirus.
Asunto(s)
Agammaglobulinemia , Infecciones por Enterovirus , Enfermedades Genéticas Ligadas al Cromosoma X , Agammaglobulinemia/diagnóstico , Agammaglobulinemia/tratamiento farmacológico , Agammaglobulinemia/epidemiología , Agammaglobulinemia/virología , Antivirales/uso terapéutico , Encéfalo/diagnóstico por imagen , Encéfalo/virología , Preescolar , Enterovirus/genética , Enterovirus/aislamiento & purificación , Infecciones por Enterovirus/diagnóstico , Infecciones por Enterovirus/tratamiento farmacológico , Infecciones por Enterovirus/epidemiología , Infecciones por Enterovirus/virología , Enfermedades Genéticas Ligadas al Cromosoma X/diagnóstico , Enfermedades Genéticas Ligadas al Cromosoma X/tratamiento farmacológico , Enfermedades Genéticas Ligadas al Cromosoma X/epidemiología , Enfermedades Genéticas Ligadas al Cromosoma X/virología , Humanos , Imagen por Resonancia Magnética , Masculino , Éteres Fenílicos/uso terapéuticoRESUMEN
BACKGROUND: The occurrence of respiratory tract viral infections in patients with primary hypogammaglobulinemia has not been studied. OBJECTIVE: We conducted a prospective 12-month follow-up study of respiratory tract infections in 12 adult patients with primary hypogammaglobulinemia. METHODS: Nasal swab samples and induced sputum samples were taken at the onset of acute respiratory tract infection and every 3 months thereafter. Samples were tested for bacteria and viruses. PCR tests were performed for 15 respiratory tract viruses. In case the results for rhinovirus were positive, follow-up nasal swab samples were taken every 2 weeks until rhinoviral PCR results became negative. Patients completed symptom diaries, which were collected every month. The spouses of the patients served as healthy control subjects. RESULTS: During the 12-month period, the 12 patients had 65 episodes of acute respiratory tract infections, and the 11 spouses had 12 acute episodes (P < .001). Respiratory tract viruses were found in sputum in 54% of the infections. Rhinovirus was the most common virus. In more than half of our patients, rhinoviral PCR results stayed positive for more than 2 months. The most long-acting persistence with the same rhinovirus was 4 months. CONCLUSIONS: Despite adequate immunoglobulin replacement therapy, patients with primary hypogammaglobulinemia have increased susceptibility to respiratory tract viral infections. Rhinoviral infections are frequent and prolonged.
Asunto(s)
Agammaglobulinemia/complicaciones , Infecciones del Sistema Respiratorio/epidemiología , Virosis/epidemiología , Adulto , Agammaglobulinemia/virología , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Recurrencia , Infecciones del Sistema Respiratorio/etiología , Rhinovirus/aislamiento & purificación , Esputo/microbiología , Esputo/virologíaRESUMEN
X-linked agammaglobulinaemia (XLA) is a humoral immunodeficiency syndrome characterized from childhood by the absence of circulating B lymphocytes, absent or reduced levels of serum immunoglobulin and recurrent bacterial infections. For many affected patients, regular treatment with immunoglobulin is life saving. Hepatitis C viral (HCV) infection acquired through contaminated blood products is widely described in this patient cohort. The natural history of HCV infection in patients with XLA tends to follow a more rapid and aggressive course compared to immunocompetent individuals. Furthermore, standard anti-viral therapy appears to be less efficacious in this patient cohort. Here we report the cases of two brothers with XLA who contracted HCV through contaminated blood products. They were treated with a six month course of Interferon alpha-2b and Ribavirin. We report a sustained virologic response five years after completing treatment.
Asunto(s)
Agammaglobulinemia/virología , Antivirales/uso terapéutico , Enfermedades Genéticas Ligadas al Cromosoma X/virología , Hepatitis C/sangre , Hepatitis C/tratamiento farmacológico , Hepatitis C/prevención & control , Adulto , Agammaglobulinemia/complicaciones , Agammaglobulinemia/etiología , Agammaglobulinemia/genética , Comorbilidad , Contaminación de Medicamentos , Enfermedades Genéticas Ligadas al Cromosoma X/complicaciones , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Hepatitis C/etiología , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Masculino , Proteínas Recombinantes , Recurrencia , Ribavirina/uso terapéutico , HermanosRESUMEN
Reported herein is a case of type AB thymoma accompanied by pure red cell aplasia (PRCA) and Good syndrome. The patient was a 55-year-old woman who was found to be anemic and to have an abnormal shadow at the left pulmonary hilus on routine medical examination. Bone marrow aspiration was performed and she was diagnosed as having PRCA. She also had hypogammaglobulinemia. The anemia was temporarily cured with oral prednisolone and cyclosporin A, and the patient underwent total thymectomy. The tumor was type AB thymoma, composed mainly of type A components; widespread spindle cell components showed slight to moderate infiltration of immature T-cells. In addition, CMV inclusion bodies were scattered throughout this tumor. The CMV-infected cells were tumor cells, because they were positive for pancytokeratin and negative for CD34. Several cases of Good syndrome with widespread CMV infection have been reported, but it is extremely rare for CMV-inclusion bodies to be found in tumor cells. No thymoma cases involving CMV infection of tumor cells have been reported.
Asunto(s)
Infecciones por Citomegalovirus/patología , Síndromes de Inmunodeficiencia/patología , Aplasia Pura de Células Rojas/patología , Timoma/patología , Timoma/virología , Neoplasias del Timo/patología , Neoplasias del Timo/virología , Agammaglobulinemia/patología , Agammaglobulinemia/virología , Terapia Combinada , Ciclosporina/uso terapéutico , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/complicaciones , Infecciones por Citomegalovirus/terapia , Femenino , Humanos , Inmunohistoquímica , Síndromes de Inmunodeficiencia/terapia , Síndromes de Inmunodeficiencia/virología , Cuerpos de Inclusión Viral/patología , Persona de Mediana Edad , Prednisolona/uso terapéutico , Aplasia Pura de Células Rojas/tratamiento farmacológico , Aplasia Pura de Células Rojas/virología , Timectomía , Timoma/terapia , Neoplasias del Timo/terapiaRESUMEN
The evolution of the Sabin strain of type 1 poliovirus in a hypogammaglobulinemia patient for a period of 649 days is described. Twelve poliovirus isolates from sequential stool samples encompassing days 21 to 649 after vaccination with Sabin 1 were characterized in terms of their antigenic properties, virulence in transgenic mice, sensitivity for growth at high temperatures, and differences in nucleotide sequence from the Sabin 1 strain. Poliovirus isolates from the immunodeficient patient evolved gradually toward non-temperature-sensitive and neurovirulent phenotypes, accumulating mutations at key nucleotide positions that correlated with the observed reversion to biological properties typical of wild polioviruses. Analysis of plaque-purified viruses from stool samples revealed complex genetic and evolutionary relationships between the poliovirus strains. The generation of various coevolving genetic lineages incorporating different mutations was observed at early stages of virus excretion. The main driving force for genetic diversity appeared to be the selection of mutations at attenuation sites, particularly in the 5' noncoding region and the VP1 BC loop. Recombination between virus strains from the two main lineages was observed between days 63 and 88. Genetic heterogeneity among plaque-purified viruses at each time point seemed to decrease with time, and only viruses belonging to a unique genotypic lineage were seen from day 105 after vaccination. The relevance of vaccine-derived poliovirus strains for disease surveillance and future polio immunization policies is discussed in the context of the Global Polio Eradication Initiative.
Asunto(s)
Agammaglobulinemia/virología , Evolución Molecular , Vacuna Antipolio Oral/administración & dosificación , Poliovirus/clasificación , Poliovirus/genética , Animales , Antígenos Virales/inmunología , Secuencia de Bases , Línea Celular , Preescolar , Heces/virología , Humanos , Inmunización , Masculino , Ratones , Ratones Transgénicos , Datos de Secuencia Molecular , Mutación , Filogenia , Poliovirus/aislamiento & purificación , Poliovirus/patogenicidad , Dinámica Poblacional , Análisis de Secuencia de ADN , Temperatura , Factores de Tiempo , Virulencia , Esparcimiento de VirusRESUMEN
OBJECTIVE: To study bacteria and viruses in maxillary sinuses of patients with primary hypogammaglobulinemia receiving immunoglobulin therapy. DESIGN: Prospective cross-sectional study during 6 months. SETTING: Tertiary care university hospital. PATIENTS: Seventeen patients with primary hypogammaglobulinemia (10 males and 7 females; mean age, 39 years [age range, 11-71 years]). Sixteen patients had common variable immunodeficiency, and 1 patient had X-linked agammaglobulinemia. MAIN OUTCOME MEASURES: Magnetic resonance imaging and x-ray imaging of paranasal sinuses when patients did not have signs of acute infection and reevaluation 6 months later. Maxillary sinus aspiration and lavage were performed at a follow-up visit. Sinus fluid analysis for bacteria and viruses was performed by culture and by polymerase chain reaction. A questionnaire on symptoms related to sinusitis was administered during the follow-up period. RESULTS: Among 17 patients, 9 (53%) had radiologically defined sinusitis without subjective symptoms at study enrollment. At reevaluation 6 months later, radiological findings remained unchanged in two thirds of the patients. Among 15 patients, bacteria were found in sinus lavage samples from 13 patients, and viruses were found in samples from 7 patients. Eight patients had 2 pathogens or more on bacterial culture. Rhinovirus was identified from sinus lavage samples in 5 patients (33%), enterovirus in 3 patients (20%), and respiratory syncytial virus in 1 patient (7%). Pathogenic bacteria were found in maxillary sinuses of all patients who tested positive for rhinovirus and enterovirus. No fungi were found. During the follow-up period, 6 patients reported mucopurulent drainage. CONCLUSIONS: Bacteria and viruses were commonly found in maxillary sinuses of patients with primary hypogammaglobulinemia. Yearly evaluation by an ear, nose, and throat surgeon is recommended.
Asunto(s)
Agammaglobulinemia/microbiología , Bacterias/clasificación , Seno Maxilar/microbiología , Virus/clasificación , Adolescente , Adulto , Agammaglobulinemia/virología , Anciano , Niño , Inmunodeficiencia Variable Común/microbiología , Inmunodeficiencia Variable Común/virología , Estudios Transversales , Enterovirus/aislamiento & purificación , Femenino , Estudios de Seguimiento , Enfermedades Genéticas Ligadas al Cromosoma X/microbiología , Enfermedades Genéticas Ligadas al Cromosoma X/virología , Haemophilus influenzae/aislamiento & purificación , Humanos , Imagen por Resonancia Magnética , Masculino , Seno Maxilar/diagnóstico por imagen , Seno Maxilar/virología , Sinusitis Maxilar/microbiología , Sinusitis Maxilar/virología , Persona de Mediana Edad , Estudios Prospectivos , Radiografía , Rhinovirus/aislamiento & purificaciónRESUMEN
The question of whether viruses persist after apparent clearance of infection remains unanswered. Here, we describe a patient with hypogammaglobulinemia whose acute hepatitis C virus (HCV) infection appeared to resolve after receipt of interferon therapy, relapse immediately, and then clear spontaneously--only to relapse after receipt of corticosteroid therapy, and clear again, 8.5 years later. Sequencing indicated that the viruses detected during each relapse were virtually identical, with the hypervariable region 1 of E2 appearing to be monoclonal, which is typical of patients with hypogammaglobulinemia. Nonstructural 5A sequences exhibited quasispecies diversity initially but, after 8.5 years, had become monoclonal. The prolonged period of negativity for HCV RNA followed by relapse suggests that HCV may persist in apparent sustained viral responders.
Asunto(s)
Agammaglobulinemia/complicaciones , Hepacivirus/aislamiento & purificación , Hepatitis C/virología , Corticoesteroides/uso terapéutico , Adulto , Agammaglobulinemia/virología , Alanina Transaminasa/sangre , Secuencia de Aminoácidos , Antivirales/farmacología , Antivirales/uso terapéutico , Femenino , Hepatitis C/complicaciones , Hepatitis C/tratamiento farmacológico , Humanos , Interferones/farmacología , Interferones/uso terapéutico , Mutación , Polimorfismo Genético , ARN Viral/genética , ARN Viral/aislamiento & purificación , Recurrencia , Análisis de Secuencia de ADN , Homología de Secuencia , Proteínas del Envoltorio Viral/genética , Proteínas no Estructurales Virales/genéticaRESUMEN
A fraction of HIV is associated with erythrocytes even when the virus becomes undetectable in plasma under antiretroviral therapy. The aim of the present work was to further characterize this association in vitro. We developed an in vitro model to study the factors involved in the adherence of HIV-1 to erythrocytes. Radiolabeled HIV-1 (HIV) and preformed HIV-1/anti-HIV immune complexes (HIV-IC) were opsonized in various human sera, purified using sucrose density gradient ultracentrifugation, and incubated with human erythrocytes. We observed that, when opsonized in normal human serum, not only HIV-IC, but also HIV, bound to erythrocytes, although the adherence of HIV was lower than that of HIV-IC. The adherence was abolished when the complement system was blocked, but was maintained in hypogammaglobulinemic sera. Complement-deficient sera indicated that both pathways of complement were important for optimal adherence. No adherence was seen in C1q-deficient serum, and the adherence of HIV was reduced when the alternative pathway was blocked using anti-factor D Abs. The adherence could be inhibited by an mAb against complement receptor 1. At supraphysiological concentrations, purified C1q mediated the binding of a small fraction of HIV and HIV-IC to erythrocytes. In conclusion, HIV-IC bound to erythrocytes as other types of IC do when exposed to complement. Of particular interest was that HIV alone bound also to erythrocytes in a complement/complement receptor 1-dependent manner. Thus, erythrocytes may not only deliver HIV-IC to organs susceptible to infection, but free HIV as well. This may play a crucial role in the progression of the primary infection.
Asunto(s)
Proteínas del Sistema Complemento/fisiología , Eritrocitos/inmunología , Eritrocitos/virología , VIH-1/inmunología , Agammaglobulinemia/sangre , Agammaglobulinemia/inmunología , Agammaglobulinemia/virología , Complejo Antígeno-Anticuerpo/sangre , Sitios de Unión de Anticuerpos , Adhesión Celular/inmunología , Línea Celular , Complemento C1q/fisiología , Vía Alternativa del Complemento/inmunología , Relación Dosis-Respuesta Inmunológica , Eritrocitos/metabolismo , Anticuerpos Anti-VIH/sangre , Antígenos VIH/sangre , Antígenos VIH/inmunología , VIH-1/metabolismo , Humanos , Reacción de Inmunoadherencia , Sueros Inmunes/metabolismo , Receptores de Complemento 3b/fisiologíaAsunto(s)
Infecciones por Adenoviridae/complicaciones , Agammaglobulinemia/complicaciones , Agammaglobulinemia/inmunología , Linfocitos B/citología , Linfocitos B/inmunología , Trasplante de Médula Ósea , Infecciones por Herpesviridae/complicaciones , Agammaglobulinemia/virología , Niño , Femenino , Humanos , Recuento de LinfocitosRESUMEN
A patient with agammaglobulinemia developed acute hepatitis that progressed to chronic liver disease with high levels of hepatitis B virus (HBV) DNA in the absence of detectable HBsAg. Sequencing of the a determinant region of HBsAg revealed multiple amino acid substitutions that, unusually, also included a substitution at position 122 that defines subtype specificity. All of these mutations had a profound effect on the antigenicity of this region, which led to the complete failure of variant detection by commercially available routine diagnostic assays or laboratory-based monoclonal antibody assays.
Asunto(s)
Agammaglobulinemia/virología , Antígenos de Superficie de la Hepatitis B/genética , Mutación , Anticuerpos Monoclonales/inmunología , Secuencia de Bases , Anticuerpos contra la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/química , Antígenos de Superficie de la Hepatitis B/inmunología , Virus de la Hepatitis B/clasificación , Virus de la Hepatitis B/genética , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Análisis de Secuencia de ADNRESUMEN
Patients with agammaglobulinemia may excrete enteroviruses, including vaccine-derived poliovirus, for prolonged periods of time. This poses a risk to the patients but it also may pose a risk to the population after eradication of poliovirus and the cessation of routine vaccination. To assess this risk, a pilot study was performed to identify potential poliovirus long-term excretors in a cohort of 38 patients with a definite/presumptive diagnosis of X-linked agammaglobulinemia (XLA). Stool samples were analyzed to detect any polio or other enteroviruses replicating in the gut and neutralizing antibodies against polioviruses were measured in the sera. No viruses were isolated from the stool samples and most sera had neutralizing antibody levels against all three poliovirus serotypes considered by the WHO to be protective in immunocompetent individuals. This suggests that long-term excretion of enteroviruses in patients with agammaglobulinemia is relatively uncommon.
Asunto(s)
Agammaglobulinemia/virología , Portador Sano , Huésped Inmunocomprometido , Poliovirus/aislamiento & purificación , Esparcimiento de Virus , Adolescente , Adulto , Anticuerpos Antivirales/sangre , Niño , Preescolar , Heces/virología , Humanos , Masculino , Proyectos Piloto , Vacuna Antipolio Oral/inmunologíaRESUMEN
The molecular and antigenic properties of a Sabin-like type 2 poliovirus, isolated from the stool samples of a 2-year-old agammaglobulinaemic child who developed paralysis 1 year after receiving the third dose of oral poliovirus vaccine, were analysed. The virus revealed 0.88 % genome variation in the VP1 region compared with the standard reference strain, compatible with replication of the virus in the intestine over approximately 1 year. The typical mutations in the 5'NCR and VP1 associated with reversion to neurovirulence for Sabin type 2 poliovirus were found. Despite this, the virus was characterized by both PCR and ELISA tests as Sabin-like and showed temperature sensitivity and neurovirulence in transgenic mice typical of the Sabin type 2 vaccine strain. Gammaglobulin replacement therapy led rapidly to virus clearance, which, when combined with treatment with the antiviral drug pleconaril, stopped virus excretion; no further virus shedding occurred. This is the first case of poliomyelitis and long-term excretion from an immunodeficient patient to be reported in Italy through the active 'Acute Flaccid Paralysis' surveillance system.